Biblio Discovery — Demo Discovery Service

13 results for "James Fingleton"

Showing 1–13 · 0.60 seconds · RSS

  1. Journal Article

    Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

    Peter Daley-Yates; Brian Keppler; Amanda Baines et al.

    Respiratory Research, Vol. 23 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and lipidomic profile following treatment with FF/VI or…

  2. Journal Article

    Efficacy of Micromobile Foot Compression Device in Increasing Lower Limb Venous Blood Flow

    Thomas Charles; Stephen Mackintosh; James Fingleton et al.

    International Journal of Vascular Medicine, Vol. 2013 · 2013 · English · DOAJ Scopus

    Background. A novel, micromobile foot compression device (MMC) has been developed to reduce the risk of venous thromboembolism associated with prolonged seated immobility. Objective. To compare the efficacy of the MMC with graduated compression stockings in augmenting lower limb venous blood flow…

  3. Journal Article

    ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis

    Lee Hatter; Pepa Bruce; Irene Braithwaite et al.

    ERJ Open Research, Vol. 7 No. 1 · 2021 · English · DOAJ Scopus

    Background The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β2-agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two…

  4. Journal Article

    Patient preferences for asthma management: a qualitative study

    Matire Harwood; James Fingleton; Richard Beasley et al.

    BMJ Open, Vol. 10 No. 8 · 2020 · English · DOAJ Scopus

    Objective Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients’ attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and…

  5. Journal Article

    Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study

    Rachel Varughese; Ruth Semprini; Claire Munro et al.

    Allergy, Asthma & Clinical Immunology, Vol. 14 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background In asthma, serum periostin may potentially be used as a biomarker in the management of patients with Type-2 eosinophilic airway inflammation. However, serum periostin may be influenced by factors other than Type 2 inflammation, potentially confounding its interpretation. We…

  6. Journal Article

    Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial

    George Bardsley; Janine Pilcher; Steven McKinstry et al.

    BMC Pulmonary Medicine, Vol. 18 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88–92%. Optimally titrated oxygen regimens…

  7. Journal Article

    Serum periostin levels in adults of Chinese descent: an observational study

    Evan Tan; Rachel Varughese; Ruth Semprini et al.

    Allergy, Asthma & Clinical Immunology, Vol. 14 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Periostin has been shown to be a marker of Type 2 airway inflammation, associated with airway eosinophilia. It has a potential role in identifying asthmatics who may be responsive to treatment with monoclonal antibody therapy directed against Type 2 cytokines, such as…

  8. Journal Article

    Randomised controlled trial of topical kanuka honey for the treatment of rosacea

    James Fingleton; Mark Weatherall; Richard Beasley et al.

    BMJ Open, Vol. 5 No. 6 · 2015 · English · DOAJ Scopus

    Objective To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea.Design Randomised controlled trial with blinded assessment of primary outcome variable.Setting Outpatient primary healthcare population from 5 New Zealand…

  9. Journal Article

    Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial

    Nick Shortt; James Fingleton; Mark Weatherall et al.

    BMJ Open, Vol. 11 No. 11 · 2021 · English · DOAJ Scopus

    Background The common cold is the most common infectious disease affecting humans and has a substantial economic impact on society. Human rhinoviruses, which cause almost two-thirds of colds, have demonstrated temperature-dependent replication which is optimal between 33°C and 35°C.Methods This…

  10. Journal Article

    Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

    George Bardsley; Peter Daley-Yates; Amanda Baines et al.

    Respiratory Research, Vol. 19 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed…

  11. Journal Article

    Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

    James Fingleton; Mark Weatherall; Richard Beasley et al.

    BMJ Open Respiratory Research, Vol. 9 No. 1 · 2022 · English · DOAJ Scopus

    Background In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta2-agonist (SABA) reliever in adolescent and adult asthma, but results in slightly worse control of…